Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The companies will analyze RNA sequencing data from Scipher to identify biomarkers for patient stratification and drug development.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Most adults in the US would take a blood test to assess whether they will develop Alzheimer's, according to the survey, ...

When patients with solid tumors had the same liquid- and tissue-based test findings, patients had better outcomes on molecular tumor board-guided therapy.

The cost savings will allow the firm to hire new employees who can support clinical trials of its DMD candidates and advance other therapeutic programs.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

Researchers at AACR's annual meeting said they hope the vaccine will show stronger efficacy in patients with minimal residual disease.

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.